Article
Biologics License Application Accepted for Vic-Trastuzumab Duocarmazine in HER2+ Advanced Breast Cancer
Rating:
0.0
Views:
45
Likes:
1
Library:
1
The FDA has accepted a biologics license application for vic-trastuzumab duocarmazine for patients with HER2-positive unresectable locally advanced or metastatic breast cancer.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value